| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
DRAK2-IN-1 targets DRAK2 (Death-associated protein kinase-related apoptosis-inducing kinase 2), a member of the DAPK (Death-Associated Protein Kinase) family of serine/threonine kinases. It acts as a potent, selective, and ATP-competitive inhibitor. The compound has an IC50 of 3 nM and a Ki of 0.26 nM for DRAK2. It also inhibits DRAK1 with an IC50 of 51 nM. DRAK2 is involved in apoptosis and immune regulation, and its inhibition can modulate these processes.
|
|---|---|
| ln Vitro |
In vitro studies have characterized DRAK2-IN-1 as a potent and selective inhibitor of DRAK2. It has an IC50 of 3 nM and a Ki of 0.26 nM for DRAK2. The compound also inhibits DRAK1 with an IC50 of 51 nM. Its selectivity for DRAK2 over other kinases has been confirmed in kinase profiling assays. The compound's ATP-competitive mechanism has been demonstrated in biochemical assays. DRAK2-IN-1 is used to study the biological functions of DRAK2 in various cellular contexts.
|
| ln Vivo |
In vivo studies of DRAK2-IN-1 are limited, as the compound is primarily used as a research tool for in vitro studies. As a DRAK2 inhibitor, it could potentially modulate apoptosis and immune responses in animal models. However, specific in vivo efficacy data are not extensively reported. The compound's utility in vivo would depend on its pharmacokinetic properties and bioavailability. Further studies are needed to characterize its in vivo activity and therapeutic potential.
|
| Enzyme Assay |
The in vitro enzyme assay for DRAK2-IN-1 involves measuring the kinase activity of DRAK2 in the presence of the compound. Purified DRAK2 kinase is incubated with a peptide substrate and ATP. The phosphorylation of the substrate is measured using methods such as radiometric assays, fluorescence polarization, or ELISA. Varying concentrations of DRAK2-IN-1 are added to determine the IC50 and Ki values. The IC50 of 3 nM and Ki of 0.26 nM are determined from dose-response curves. Data are analyzed using nonlinear regression models.
|
| Cell Assay |
In vitro cellular assays for DRAK2-IN-1 are conducted using cell lines expressing DRAK2. Cells are treated with varying concentrations of DRAK2-IN-1. DRAK2 activity is assessed by measuring the phosphorylation of its substrates using Western blotting with phospho-specific antibodies. Cell viability and apoptosis are evaluated using standard assays such as MTT, LDH release, or caspase activity assays. The compound's effects on DRAK2-mediated signaling pathways are assessed. All experiments are performed in triplicate with appropriate vehicle controls.
|
| Animal Protocol |
In vivo animal studies for DRAK2-IN-1 are not extensively reported. As a DRAK2 inhibitor, it could be evaluated in mouse models of cancer, autoimmune diseases, or other conditions where DRAK2 plays a role. Typical study designs would involve administration of the compound via intraperitoneal or oral routes in disease model mice. Disease progression, immune cell function, and apoptosis markers would be assessed. However, specific published in vivo protocols for DRAK2-IN-1 are not available in the provided sources.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for DRAK2-IN-1 are not extensively reported. The compound has a molecular weight of 376.41 g/mol and a molecular formula of C21H20N4O3. It is a small molecule with properties suitable for oral bioavailability. Specific pharmacokinetic parameters such as half-life, Cmax, and bioavailability are not provided in the available sources. The compound is for research use only. Storage recommendations are not provided in the available sources.
|
| Toxicity/Toxicokinetics |
Toxicology data for DRAK2-IN-1 are not extensively reported. As a DRAK2 inhibitor, the compound's safety profile would be related to its effects on apoptosis and immune regulation. DRAK2 is involved in immune cell function, and its inhibition could potentially modulate immune responses. Specific toxicity data, including LD50 values and organ toxicity profiles, are not available. The compound is for research use only.
|
| References | |
| Additional Infomation |
DRAK2-IN-1 is a potent, selective, and ATP-competitive inhibitor of DRAK2 with an IC50 of 3 nM and a Ki of 0.26 nM. It also inhibits DRAK1 with an IC50 of 51 nM. The compound has a molecular weight of 376.41 g/mol and a molecular formula of C21H20N4O3. DRAK2-IN-1 is a research tool for studying the role of DRAK2 in apoptosis, immune regulation, and cancer. It is for research use only.
|
| Molecular Formula |
C21H20N4O3
|
|---|---|
| Molecular Weight |
376.408504486084
|
| Exact Mass |
376.153
|
| CAS # |
871837-60-4
|
| PubChem CID |
136175114
|
| Appearance |
Orange to red solid powder
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
574
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O/N=C1/C2C(=CC=CC=2)N/C/1=C1\C2C(=CC=C(NC(=O)CCCC)C=2)NC\1=O
|
| InChi Key |
ZFZLSKZDOULLMO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H20N4O3/c1-2-3-8-17(26)22-12-9-10-16-14(11-12)18(21(27)24-16)20-19(25-28)13-6-4-5-7-15(13)23-20/h4-7,9-11,23-24,27H,2-3,8H2,1H3,(H,22,26)
|
| Chemical Name |
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]pentanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~265.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (13.28 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (5.53 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6567 mL | 13.2834 mL | 26.5668 mL | |
| 5 mM | 0.5313 mL | 2.6567 mL | 5.3134 mL | |
| 10 mM | 0.2657 mL | 1.3283 mL | 2.6567 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
